Advertisement

Standard of Care Relapsed DLBCL

  • Kayane Mheidly
  • Roch HouotEmail author
  • Michael Scordo
  • Craig Moskowitz
Chapter
Part of the Hematologic Malignancies book series (HEMATOLOGIC)

Abstract

At least 50% of patients with diffuse large B-cell lymphoma (DLBCL) experience long-term disease-free survival [1, 2]. Although the addition of anti-CD20 monoclonal antibody rituximab (R) to conventional chemotherapy has dramatically improved event-free survival (EFS) and overall survival (OS) in DLBCL [3], a significant proportion of patients are refractory or relapse following first-line treatment.

References

  1. 1.
    Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23(18):4117–26.  https://doi.org/10.1200/JCO.2005.09.131.CrossRefPubMedGoogle Scholar
  2. 2.
    Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379–91.  https://doi.org/10.1016/S1470-2045(06)70664-7.CrossRefPubMedGoogle Scholar
  3. 3.
    Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–90.  https://doi.org/10.1200/JCO.2010.28.1618.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Telio D, Fernandes K, Ma C, et al. Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors. Leuk Lymphoma. 2012;53(5):836–41.  https://doi.org/10.3109/10428194.2011.643404.CrossRefPubMedGoogle Scholar
  5. 5.
    Larouche J-F, Berger F, Chassagne-Clément C, et al. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. J Clin Oncol. 2010;28(12):2094–100.  https://doi.org/10.1200/JCO.2009.24.5860.CrossRefPubMedGoogle Scholar
  6. 6.
    Cohen JB, Behera M, Thompson CA, Flowers CR. Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma. Blood. 2017;129(5):561–4.  https://doi.org/10.1182/blood-2016-08-685073.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2003;102(6):1989–96.  https://doi.org/10.1182/blood-2002-12-3837.CrossRefPubMedGoogle Scholar
  8. 8.
    Guglielmi C, Gomez F, Philip T, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol. 1998;16(10):3264–9.  https://doi.org/10.1200/JCO.1998.16.10.3264.CrossRefPubMedGoogle Scholar
  9. 9.
    Hitz F, Connors JM, Gascoyne RD, et al. Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment. Ann Hematol. 2015;94(11):1839–43.  https://doi.org/10.1007/s00277-015-2467-z.CrossRefPubMedGoogle Scholar
  10. 10.
    Crump M, Neelapu S, Farooq U, et al. Outcomes in refractory aggressive diffuse large B cell lymphoma (DLBCL): results from the International SCHOLAR-1 Study. Clin Lymphoma Myeloma Leuk. 2016;16:S101.  https://doi.org/10.1016/j.clml.2016.07.147.CrossRefGoogle Scholar
  11. 11.
    Thieblemont C, Briere J, Mounier N, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol. 2011;29(31):4079–87.  https://doi.org/10.1200/JCO.2011.35.4423.CrossRefPubMedGoogle Scholar
  12. 12.
    Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32(31):3490–6.  https://doi.org/10.1200/JCO.2013.53.9593.CrossRefPubMedGoogle Scholar
  13. 13.
    Mounier N, El Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica. 2013;98(11):1726–31.  https://doi.org/10.3324/haematol.2013.090597.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ohmachi K, Niitsu N, Uchida T, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2013;31(17):2103–9.  https://doi.org/10.1200/JCO.2012.46.5203.CrossRefPubMedGoogle Scholar
  15. 15.
    Crump M, Baetz T, Couban S, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer. 2004;101(8):1835–42.  https://doi.org/10.1002/cncr.20587.CrossRefPubMedGoogle Scholar
  16. 16.
    Baetz T, Chen BE, Couban S, et al. Addition of rituximab to salvage chemotherapy in aggressive CD20+ lymphoma prior to autologous stem cell transplant (ASCT): a cohort comparison from the NCIC CTG study LY.12. Blood. 2014;124(21):1712.Google Scholar
  17. 17.
    Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–5.  https://doi.org/10.1056/NEJM199512073332305.CrossRefPubMedGoogle Scholar
  18. 18.
    Buadi FK, Micallef IN, Ansell SM, et al. Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2006;37(11):1017–22.  https://doi.org/10.1038/sj.bmt.1705371.CrossRefPubMedGoogle Scholar
  19. 19.
    Jantunen E, Itälä M, Lehtinen T, et al. Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients. Eur J Haematol. 2006;76(3):245–50.  https://doi.org/10.1111/j.1600-0609.2005.00605.x.CrossRefPubMedGoogle Scholar
  20. 20.
    Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125(1):22–32.  https://doi.org/10.1182/blood-2014-05-577189.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Cortelazzo S, Rambaldi A, Rossi A, et al. Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin’s lymphoma. Br J Haematol. 2001;114(2):333–41. http://www.ncbi.nlm.nih.gov/pubmed/11529852. Accessed 28 Jun 2017.CrossRefGoogle Scholar
  22. 22.
    Filmont J-E, Gisselbrecht C, Cuenca X, et al. The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer. 2007;110(6):1361–9.  https://doi.org/10.1002/cncr.22911.CrossRefPubMedGoogle Scholar
  23. 23.
    Dickinson M, Hoyt R, Roberts AW, et al. Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy: research paper. Br J Haematol. 2010;150(1):39–45.  https://doi.org/10.1111/j.1365-2141.2010.08162.x.CrossRefPubMedGoogle Scholar
  24. 24.
    Roland V, Bodet-Milin C, Moreau A, et al. Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients. Bone Marrow Transplant. 2011;46(3):393–9.  https://doi.org/10.1038/bmt.2010.130.CrossRefPubMedGoogle Scholar
  25. 25.
    Sauter CS, Matasar MJ, Meikle J, et al. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood. 2015;125(16):2579–81.  https://doi.org/10.1182/blood-2014-10-606939.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Ottinger HD, Beelen DW, Scheulen B, Schaefer UW, Grosse-Wilde H. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood. 1996;88(7):2775–9. http://www.ncbi.nlm.nih.gov/pubmed/8839875.PubMedGoogle Scholar
  27. 27.
    Vellenga E, van Agthoven M, Croockewit AJ, et al. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. Br J Haematol. 2001;114(2):319–26. http://www.ncbi.nlm.nih.gov/pubmed/11529850. Accessed 28 Jun 2017.CrossRefGoogle Scholar
  28. 28.
    Vose JM, Sharp G, Chan WC, et al. Autologous transplantation for aggressive non-Hodgkin’s lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol. 2002;20(9):2344–52.  https://doi.org/10.1200/JCO.2002.09.138.CrossRefPubMedGoogle Scholar
  29. 29.
    Jacobsen E, Freedman A. B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma. Lancet Oncol. 2004;5(12):711–7.  https://doi.org/10.1016/S1470-2045(04)01646-8.CrossRefPubMedGoogle Scholar
  30. 30.
    Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011(1):498–505.  https://doi.org/10.1182/asheducation-2011.1.498.CrossRefPubMedGoogle Scholar
  31. 31.
    Vose JM, Bierman PJ, Enke C, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23(3):461–7.  https://doi.org/10.1200/JCO.2005.05.117.CrossRefPubMedGoogle Scholar
  32. 32.
    Vose JM, Carter S, Burns LJ, et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol. 2013;31(13):1662–8.  https://doi.org/10.1200/JCO.2012.45.9453.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Chen Y-B, AA L, Logan BR, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(6):1046–53.  https://doi.org/10.1016/j.bbmt.2015.02.005.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011;118(12):3419–25.  https://doi.org/10.1182/blood-2011-04-351924.CrossRefPubMedGoogle Scholar
  35. 35.
    Cote GM, Hochberg EP, Muzikansky A, et al. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2012;18(1):76–83.  https://doi.org/10.1016/j.bbmt.2011.07.006.CrossRefPubMedGoogle Scholar
  36. 36.
    Chen Y-B, Batchelor T, Li S, et al. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer. 2015;121(2):226–33.  https://doi.org/10.1002/cncr.29023.CrossRefPubMedGoogle Scholar
  37. 37.
    Welch MR, Sauter CS, Matasar MJ, et al. Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide. Leuk Lymphoma. 2015;56(2):361–7.  https://doi.org/10.3109/10428194.2014.916800.CrossRefPubMedGoogle Scholar
  38. 38.
    Scordo M, Bhatt V, Hsu M, et al. A comprehensive assessment of toxicities in patients with central nervous system lymphoma undergoing autologous stem cell transplantation using thiotepa, busulfan, and cyclophosphamide conditioning. Biol Blood Marrow Transplant. 2017;23(1):38–43.  https://doi.org/10.1016/j.bbmt.2016.09.024.CrossRefPubMedGoogle Scholar
  39. 39.
    Dhakal S, Bates JE, Casulo C, et al. Patterns and timing of failure for diffuse large B-cell lymphoma after initial therapy in a cohort who underwent autologous bone marrow transplantation for relapse. Int J Radiat Oncol Biol Phys. 2016;96(2):372–8.  https://doi.org/10.1016/j.ijrobp.2016.05.021.CrossRefPubMedGoogle Scholar
  40. 40.
    Hoppe BS, Moskowitz CH, Filippa DA, et al. Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity. J Clin Oncol. 2008;26(11):1858–64.  https://doi.org/10.1200/JCO.2007.15.4773.CrossRefPubMedGoogle Scholar
  41. 41.
    Hoppe BS, Moskowitz CH, Zhang Z, et al. The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. Bone Marrow Transplant. 2009;43(12):941–8.  https://doi.org/10.1038/bmt.2008.408.CrossRefPubMedGoogle Scholar
  42. 42.
    Mandigers CMPW, Verdonck LF, Meijerink JPP, Dekker AW, Schattenberg AVMB, Raemaekers JMM. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant. 2003;32(12):1159–63.  https://doi.org/10.1038/sj.bmt.1704290.CrossRefPubMedGoogle Scholar
  43. 43.
    Bishop MR, Dean RM, Steinberg SM, et al. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol. 2008;19(11):1935–40.  https://doi.org/10.1093/annonc/mdn404.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Calvo-Villas JM, Martín A, Conde E, et al. Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation. Ann Oncol. 2010;21(9):1891–7.  https://doi.org/10.1093/annonc/mdq035.CrossRefPubMedGoogle Scholar
  45. 45.
    Aksentijevich I, Jones RJ, Ambinder RF, Garrett-Mayer E, Flinn IW. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006;12(9):965–72.  https://doi.org/10.1016/j.bbmt.2006.05.018.CrossRefPubMedGoogle Scholar
  46. 46.
    Lazarus HM, Zhang M-J, Carreras J, et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant. 2010;16(1):35–45.  https://doi.org/10.1016/j.bbmt.2009.08.011.CrossRefPubMedGoogle Scholar
  47. 47.
    Papageorgiou SG, Cwynarski K, Kottaridis PD. The role of allogeneic haematopoietic progenitor cell transplantation in patients with diffuse large B-cell non-Hodgkin lymphomas (DLBCL). Bone Marrow Transplant. 2013;48(10):1271–8.  https://doi.org/10.1038/bmt.2012.266.CrossRefPubMedGoogle Scholar
  48. 48.
    Bacher U, Klyuchnikov E, Le-Rademacher J, et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood. 2012;120(20):4256–62.  https://doi.org/10.1182/blood-2012-06-436725.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Faulkner RD, Craddock C, Byrne JL, et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood. 2004;103(2):428–34.  https://doi.org/10.1182/blood-2003-05-1406.CrossRefPubMedGoogle Scholar
  50. 50.
    Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 2004;104(13):3865–71.  https://doi.org/10.1182/blood-2004-03-1105.CrossRefPubMedGoogle Scholar
  51. 51.
    Sauter CS, Chou JF, Papadopoulos EB, et al. A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies. Leuk Lymphoma. 2014;55(12):2739–47.  https://doi.org/10.3109/10428194.2014.894185.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Oliansky DM, Czuczman M, Fisher RI, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant. 2011;17(1):18–9.  https://doi.org/10.1016/j.bbmt.2010.07.008.CrossRefGoogle Scholar
  53. 53.
    Gisselbrecht C, Schmitz N, Mounier N, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012;30(36):4462–9.  https://doi.org/10.1200/JCO.2012.41.9416.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Haioun C, Mounier N, Emile JF, et al. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Ann Oncol. 2009;20(12):1985–92.  https://doi.org/10.1093/annonc/mdp237.CrossRefPubMedGoogle Scholar
  55. 55.
    Ferreri AJM, Sassone M, Zaja F, et al. Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. Lancet Haematol. 2017;4(3):e137–46.  https://doi.org/10.1016/S2352-3026(17)30016-9.CrossRefPubMedGoogle Scholar
  56. 56.
    Van Den Neste E, Schmitz N, Mounier N, et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 2017;52(2):216–21.  https://doi.org/10.1038/bmt.2016.213.CrossRefGoogle Scholar
  57. 57.
    Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922–6.  https://doi.org/10.1038/nm.3884.CrossRefGoogle Scholar
  58. 58.
    Epperla N, Fenske TS, Lazarus HM, Hamadani M. Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet? Bone Marrow Transplant. 2015;50(11):1393–404.  https://doi.org/10.1038/bmt.2015.184.CrossRefPubMedGoogle Scholar
  59. 59.
    Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540–9.  https://doi.org/10.1200/JCO.2014.56.2025.CrossRefPubMedGoogle Scholar
  60. 60.
    Brudno JN, Somerville RPT, Shi V, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34(10):1112–21.  https://doi.org/10.1200/JCO.2015.64.5929.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Goebeler M-E, Knop S, Viardot A, et al. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol. 2016;34(10):1104–11.  https://doi.org/10.1200/JCO.2014.59.1586.CrossRefPubMedGoogle Scholar
  62. 62.
    Viardot A, Goebeler M-E, Hess G, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016;127(11):1410–6.  https://doi.org/10.1182/blood-2015-06-651380.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Kayane Mheidly
    • 1
  • Roch Houot
    • 2
    Email author
  • Michael Scordo
    • 3
  • Craig Moskowitz
    • 4
  1. 1.Department of Clinical HematologyRennes University Hospital, University of Rennes, CHU de Rennes PontchaillouRennesFrance
  2. 2.Department of Clinical HematologyRennes University Hospital, Inserm 1236, University of Rennes, CHU de Rennes PontchaillouRennesFrance
  3. 3.Adult Bone Marrow Transplant Service, Department of MedicineMemorial Sloan Kettering Cancer CenterNew YorkUSA
  4. 4.Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell UniversityNew YorkUSA

Personalised recommendations